

# CD BioGlyco Released One-stop Solution for HMO Research

*CD BioGlyco released one-stop solution for HMO research that can be applied in the identification and analysis of human milk components, etc.*

NYC, NY, USA, May 29, 2023

/EINPresswire.com/ -- CD BioGlyco, a biotechnology company focused on glycobiology research, now released one-stop solution for [HMO research](#) that can be applied in the identification and analysis of human milk components, study on the mechanism of infant disease, etc.

Breast milk, the best food for newborns, naturally contains various nutrients suitable for infants to digest and absorb, such as protein, fat, carbohydrates, various minerals and

vitamins and other trace elements. In addition, breast milk also contains various biologically active substances suitable for infants, such as lactoferrin, immunoglobulin, breast milk oligosaccharides, probiotics, etc., which play an important role in the health of infants. Human milk oligosaccharides (HMOs) are the third largest solid component in human breast milk, second only to lactose and fat, which have important biological functions, not only anti-infective effects on intestinal pathogenic microorganisms, but also to maintain the balance of intestinal microecology.

Oligosaccharides refer to a class of low-polymer carbohydrates that are linked by 3 to 10 monosaccharide units through glycosidic bonds to form straight or branched chains. Its general molecular formula can generally be expressed as  $(C_6H_{10}O_5)_n$ , where  $n$  is 3-10. The sweetness is generally only 30% to 60% of sucrose, which is difficult to be digested and absorbed by the intestinal tract. HMOs are found at high levels in colostrum, accounting for 24% of the total colostrum compounds. Within 2 months after birth, the concentration decreased steadily to



CD BioGlyco

15%-19%. The type, quantity and charge of HMO in the milk of different individuals are different; the same individual, in different stages of lactation, the HMO content in milk there are also difference.

With the combination of multiple techniques including chemical methods, whole-cell biotransformation (fermentation), enzyme catalysis (isolated enzyme biotransformation), and chemoenzymatic methods, CD BioGlyco now provides one-stop solution for HMO research, including:

#### HMO Separation Service

To assist clients in isolating low-abundance HMOs, CD BioGlyco offers a variety of cutting-edge technologies, such as UPLC, HPAEC, PGC, and HILIC.

#### [HMO Profiling](#)

High-accuracy, high-efficiency HMOs profiling services are offered by CD BioGlyco. Customers can select chromatography, MS, NMR, or other related technologies based on their requirements.

#### [HMO Production Service](#)

Combination of multiple technologies for multi-faceted HMO production services.

To know more detailed information about the one-stop solution of HMO research newly released by CD BioGlyco, please visit <https://www.bioglyco.com/one-stop-solution-for-hmo-research.html>.

Anna Bryan

CD BioGlyco

+1 631-749-6145

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/636437323>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.